clopidogrel has been researched along with Liver Cirrhosis in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Brophy, DF; Guzman, LA; Martin, E; Puckett, L; Siddiqui, MS; Stravitz, T; Trankle, CR; Vo, C | 1 |
| Li, YH; Wan, YM; Wu, HM; Wu, XN; Xu, Y; Xu, ZY; Yang, JH; Yang, LH | 1 |
| Abdel-Bakky, MS; Abo-Saif, AA; Mahmoud, NI; Messiha, BAS; Salehc, IG | 1 |
| Joshi, N; Kopec, AK; Luyendyk, JP; Ray, JL | 1 |
| Guzman-Reyes, S; Marasigan, B; Melnikov, V; Pivalizza, EG | 1 |
| Eskind, L; Gulati, S; Montegudo, A; Narang, T; Pierson, J; Russo, MW | 1 |
| Much, DR; Necciari, J; Nichola, P; Slugg, PH; Smith, WB; Vargas, R | 1 |
1 trial(s) available for clopidogrel and Liver Cirrhosis
| Article | Year |
|---|---|
Cirrhosis does not affect the pharmacokinetics and pharmacodynamics of clopidogrel.
Topics: Adult; Area Under Curve; Case-Control Studies; Clopidogrel; Female; Humans; Liver Cirrhosis; Male; Middle Aged; Platelet Aggregation Inhibitors; Skin Diseases; Ticlopidine; Time Factors | 2000 |
6 other study(ies) available for clopidogrel and Liver Cirrhosis
| Article | Year |
|---|---|
Clopidogrel Responsiveness in Patients With Decompensated Cirrhosis of the Liver Undergoing Pre-Transplant PCI.
Topics: Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Resistance; Humans; Liver Cirrhosis; Liver Transplantation; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Risk Factors; Time Factors; Treatment Outcome; Waiting Lists | 2020 |
Portal vein thrombosis before and after transjugular intrahepatic portosystemic shunt placement: An observational study (STROBE compliant).
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Female; Humans; Leukocyte Count; Liver Cirrhosis; Male; Middle Aged; Portal Vein; Portasystemic Shunt, Transjugular Intrahepatic; Prospective Studies; Risk Factors; Severity of Illness Index; Ticlopidine; Venous Thrombosis; Warfarin | 2017 |
Interruption of platelets and thrombin function as a new approach against liver fibrosis induced experimentally in rats.
Topics: Animals; Anticoagulants; Biomarkers; Blood Platelets; Carbon Tetrachloride; Clopidogrel; Dabigatran; Liver; Liver Cirrhosis; Male; Oxidative Stress; Rats; Thrombin | 2019 |
Inhibition of PAR-4 and P2Y12 receptor-mediated platelet activation produces distinct hepatic pathologies in experimental xenobiotic-induced cholestatic liver disease.
Topics: 1-Naphthylisothiocyanate; Animals; Chemical and Drug Induced Liver Injury; Cholestasis; Clopidogrel; Liver; Liver Cirrhosis; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Platelet Activation; Purinergic P2Y Receptor Antagonists; Receptors, Proteinase-Activated; Serotonin; Ticlopidine; Xenobiotics | 2016 |
Thrombelastograph platelet mapping in a patient receiving antiplatelet therapy.
Topics: Aspirin; Blood Coagulation Disorders; Blood Platelets; Clopidogrel; Dose-Response Relationship, Drug; Humans; Liver Cirrhosis; Platelet Aggregation Inhibitors; Point-of-Care Systems; Thrombelastography; Ticlopidine | 2010 |
Coronary artery stents and antiplatelet therapy in patients with cirrhosis.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Fatty Liver; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Stents; Ticlopidine | 2012 |